Menu
Search
|

Menu

Close
X

Dr.Reddy's Laboratories Ltd REDY.BO (Bombay Stock Exchange)

2,450.25 INR
-76.90 (-3.04%)
As of 3:39 PM IST
chart
Previous Close 2,527.15
Open 2,522.05
Volume 37,289
3m Avg Volume 79,438
Today’s High 2,522.05
Today’s Low 2,441.00
52 Week High 2,687.45
52 Week Low 1,888.00
Shares Outstanding (mil) 165.88
Market Capitalization (mil) 394,104.81
Forward P/E 32.79
Dividend (Yield %) 20.00 ( 0.84 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.64 Mean rating from 39 analysts

KEY STATS

Revenue (mm, INR)
FY19
75,540
FY18
142,810
FY17
141,961
FY16
155,682
EPS (INR)
FY19
59.840
FY18
64.598
FY17
77.480
FY16
124.559
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
32.79
33.59
Price to Sales (TTM)
vs sector
2.76
5.69
Price to Book (MRQ)
vs sector
--
5.11
Price to Cash Flow (TTM)
vs sector
17.83
23.52
Total Debt to Equity (MRQ)
vs sector
--
15.71
LT Debt to Equity (MRQ)
vs sector
--
11.53
Return on Investment (TTM)
vs sector
--
15.05
Return on Equity (TTM)
vs sector
--
16.62

EXECUTIVE LEADERSHIP

Satish Reddy
Chairman of the Board, Since 2014
Salary: Rs6,315,000.00
Bonus: --
G. Prasad
Co-Chairman of the Board, Chief Executive Officer, Managing Director, Since 2014
Salary: Rs18,515,000.00
Bonus: --
Saumen Chakraborty
President, Chief Financial Officer, Global Head - HR and IT & BPE, Since 2012
Salary: Rs28,080,000.00
Bonus: --
Sripada Chandrasekhar
President, Global Head - Human Resources, Since 2013
Salary: --
Bonus: --
Erez Israeli
Chief Operating Officer and Global Head of Generics & PSAI, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8-2-337, Road No.3 Banjara Hills
HYDERABAD     500-034

Phone: +9140.49002900

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). PSAI segment includes the Company's business of manufacturing and marketing active pharmaceutical ingredients and intermediates (API) or bulk drugs. Proprietary Products segment focuses on the research, development and manufacture of differentiated formulations and new chemical entities. These products fall within the dermatology and neurology therapeutic areas, and are marketed and sold through its subsidiary, Promius Pharma, LLC.

SPONSORED STORIES